制藥網(wǎng)>產(chǎn)品庫(kù)>原料藥中間體、制劑>生物試劑>其它試劑>>Doxorubicin hydrochloride試劑

Doxorubicin hydrochloride試劑

參考價(jià)	￥900.00-￥1600.00

參考價(jià)

￥900.00-￥1600.00

具體成交價(jià)以合同協(xié)議為準(zhǔn)

公司名稱杭州昊鑫生物科技股份有限公司
品牌MCE
型號(hào)HY-15142
所在地杭州市
廠商性質(zhì)代理商
更新時(shí)間2023/5/22 15:23:43
訪問(wèn)次數(shù)286

產(chǎn)品標(biāo)簽:

規(guī)格

10 mM * 1 mL in DMSO	990.00元	10000 支可售
50 mg	900.00元	10000 支可售
100 mg	1600.00元	10000 支可售

在線詢價(jià) 收藏產(chǎn)品查看電話同類產(chǎn)品

聯(lián)系我們時(shí)請(qǐng)說(shuō)明是制藥網(wǎng) 上看到的信息，謝謝!

索取相關(guān)資料

公司介紹主營(yíng)產(chǎn)品

杭州昊鑫生物科技股份有限公司成立于2009年初，是一家面向生命科學(xué)領(lǐng)域，從事科研機(jī)構(gòu)、高校、院所及生產(chǎn)企業(yè)所需科研試劑、耗材，儀器銷售和服務(wù)面向全國(guó)。

產(chǎn)品和服務(wù)涵蓋生命科學(xué)研究技術(shù)的諸多方面，提供覆蓋分子生物學(xué)、細(xì)胞生物學(xué)、植物學(xué)、生物化學(xué)、蛋白組學(xué)、免疫學(xué)等領(lǐng)域的實(shí)驗(yàn)產(chǎn)品以及生物技術(shù)服務(wù)等。目前一級(jí)代理品牌有：MCE（Medchemexpress）、Biochannel、AATbio、invivogen、Abnova、Atlas、Origene、Biovision、云克?。–loud-clone）、艾德萊(Aidlab)、Cayman、Jackson、Epigentek、Prospec、Sciencell、icellbioscience（賽百慷）、hkABCbio、chondrex、Mybiosource、Abbexa、Innovrsrch、HPI、Hitobiotec、Greerlabs，Ostex，4ADI，LDN等。

經(jīng)營(yíng)理念：以誠(chéng)信為本，保證產(chǎn)品質(zhì)量求生存，創(chuàng)造企業(yè)核心競(jìng)爭(zhēng)力求發(fā)展 , 堅(jiān)持用戶至上、服務(wù)至上的原則。

展開顯示更多內(nèi)容

胎牛血清、MCE抑制劑激動(dòng)劑、RNA提取試劑盒、ELISA試劑盒、重組蛋白

產(chǎn)品簡(jiǎn)介在線詢價(jià)

產(chǎn)地	進(jìn)口	級(jí)別	其他

Doxorubicin hydrochloride試劑是一種具有細(xì)胞毒性的蒽環(huán)類抗生素，是一種抗癌HL試劑。Doxorubicin hydrochloride 是一種有效的人類 DNA topoisomerase I 和 topoisomerase II 抑制劑，IC50 分別為 0.8 μM 和 2.67 μM。Doxorubicin hydrochlo

Doxorubicin hydrochloride試劑產(chǎn)品信息

注：本產(chǎn)品僅用于科研，不可用于臨床

生物活性

Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy^[1]^[2]^[3].

IC₅₀ & Target^[1]^[2]^[3]

Topoisomerase I

0.8 μM (IC₅₀)

Topoisomerase II

2.67 μM (IC₅₀)

Daunorubicins/Doxorubicins

HIV-1

體外研究
(In Vitro)

Doxorubicin hydrochloride (1-8 µM; 24 and 48 hours) decreases the viability of MCF-10F, MCF-7 and MDA-MB-231 cells in a time- and dose-dependent manner^[4].
Doxorubicin hydrochloride (1 μM; 3 and 24 hours) results in Hct-116 human colon carcinoma cells reduction in G0/G1 phase and accumulation in G2 phase^[5].
Doxorubicin hydrochloride (1 μM for MCF-10F and MDA-MB-231 cells, 4 μM for MCF-7 cells; 48 hours) induces apoptosis by upregulating Bax, caspase-8 and caspase-3 and downregulation of Bcl-2 protein expression^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:	Breast cancer cell lines MCF-10F, MCF-7 and MDA-MB-231
Concentration:	0, 1, 2, 4 and 8 μM
Incubation Time:	24 and 48 hours
Result:	IC₅₀ was 1 μM for both MCF-10F and MDA-MB-231 cell lines. IC₅₀ was 4 μM for MCF-7 cell line.

體內(nèi)研究
(In Vivo)

Treatment with Doxorubicin (2 mg/kg) or Zoledronic acid (100 μg/kg) alone does not statistically significantly decrease final tumor volume compared with saline. Mice treated with Doxorubicin plus Zoledronic acid have statistically significantly smaller final tumor volumes than those treated with Doxorubicin alone^[6].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female MF1 nu/nu mice bearing MDA-G8 breast tumor xenograft (6-week-old)^[6]
Dosage:	Doxorubicin (2 mg/kg); Zoledronic acid (100 μg/kg)
Administration:	Intravenous injection; once a week; 6 weeks
Result:	Moderate inhibition of subcutaneous tumor growth in mice that were treated with 2 mg/kg Doxorubicin alone or with 100 μg/kg Zoledronic acid alone compared to the saline control. Mice treated with Zoledronic acid and Doxorubicin together had statistically significant smaller mean tumor volumes on day 42 than those treated with Doxorubicin alone.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04535713	Sarcoma Oncology Research Center, LLC	Sarcoma	September 30, 2020	Phase 2
NCT01078441	National Cancer Institute (NCI)	Refractory Multiple Myeloma	September 2010	Phase 2
NCT01796197	Dana-Farber Cancer Institute	Breast Cancer	August 2013	Phase 2

分子量

579.98

性狀

Solid

Formula

C₂₇H₃₀ClNO₁₁

CAS 號(hào)

25316-40-9

中文名稱

結(jié)構(gòu)分類

Quinones
Anthraquinones

來(lái)源

Streptomyces peucetius var. Caesius

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

溶解性數(shù)據(jù)

In Vitro:

DMSO : 35.71 mg/mL (61.57 mM; ultrasonic and warming and heat to 60°C)

H₂O : 20 mg/mL (34.48 mM; Need ultrasonic)

配制儲(chǔ)備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	1.7242 mL	8.6210 mL	17.2420 mL
5 mM	0.3448 mL	1.7242 mL	3.4484 mL
10 mM	0.1724 mL	0.8621 mL	1.7242 mL

請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 儲(chǔ)存時(shí)，請(qǐng)?jiān)?6 個(gè)月內(nèi)使用，-20°C 儲(chǔ)存時(shí)，請(qǐng)?jiān)?1 個(gè)月內(nèi)使用。

In Vivo:

請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥方式選擇適當(dāng)?shù)娜芙夥桨?。以下溶解方案都?qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：

——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；以下溶劑前顯示的百
分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶

1.

請(qǐng)依序添加每種溶劑： 5% DMSO 40% PEG300 5% Tween-80 50% saline
Solubility: ≥ 2.75 mg/mL (4.74 mM); Clear solution
2.

請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (3.59 mM); Clear solution
3.

請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (3.59 mM); Clear solution